Patient demographics, comorbidities and symptoms, by antibody status of SARS-CoV-2
| Characteristic | All sample (n=3119) | Positive antibody (n=613) | Negative antibody (n=2,506) | P-value |
|---|---|---|---|---|
| Age, years n (%) ≤30 31–40 41–50 51–60 ≥61 | 669 (21.4%) 671 (21.5%) 812 (26.0%) 702 (22.5%) 265 (8.5%) | |||
155 (25.3%) 122 (19.9%) 183 (29.9%) 118 (19.2%) 35 (5.7%) | ||||
514 (20.5%) 549 (21.9%) 629 (25.1%) 584 (23.3%) 230 (9.2%) | ||||
<0.001 | ||||
| Sex Male, n (%) Female, n (%) | 775 (24.8%) 2,344 (75.2%) | 178 (29.0%) 435 (71.0%) | 597 (23.8%) 1,909 (76.2%) | 0.009 |
| Ethnicity (n=2,953*): White, n (%) Non-White, n (%) | ||||
1,804 (61.1%) 1,149 (38.9%) | ||||
225 (39.1%) 350 (60.9%) | ||||
1,579 (66.4%) 799 (33.6%) | ||||
<0.001 | ||||
| Symptoms (n=2,790†): No, n (%) Yes, n (%) Fever, n (%) Cough, n (%) Shortness breath, n (%) Loss smell/taste, n (%) Headache, n (%) Fatigue, n (%) Sore throat, n (%) Myalgia, n (%) Diarrhoea, n (%) Nausea/vomiting, n (%) Runny nose, n (%) Dizziness/vertigo, n (%) Back pain, n (%) Loss appetite, n (%) Chest pain/tightness, n (%) | 1,740 (62.4%) 1,050 (37.6%) 154 (4.9%) 154 (4.9%) 47 (1.5%) 62 (2.0%) 92 (2.9%) 95 (3.0%) 73 (2.3%) 104 (3.3%) 20 (0.6%) 19 (0.6%) 17 (0.5%) 5 (0.2%) 7 (0.2%) 10 (0.3%) 13 (0.4%) | 151 (26.4%) 422 (73.6%) 98 (16.0%) 84 (13.7%) 27 (4.4%) 54 (8.8%) 47 (7.7%) 58 (9.5%) 31 (5.1%) 68 (11.1%) 9 (1.5%) 14 (2.3%) 12 (2.0%) 2 (0.3%) 5 (0.8%) 10 (1.6%) 7 (1.1%) | 1,589 (71.7%) 628 (28.3%) 56 (2.2%) 70 (2.8%) 20 (0.8%) 8 (0.3%) 45 (1.8%) 37 (1.5%) 42 (1.7%) 36 (1.4%) 11 (0.4%) 5 (0.2%) 5 (0.2%) 3 (0.1%) 2 (0.1%) 0 6 (0.2%) | <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.009 <0.001 <0.001 0.26 0.004 – 0.006 |
| Staff group Admin and estates Clinical support Medical Nursing and midwifery Other clinical registered | 833 (26.7%) 615 (19.7%) 459 (14.7%) 951 (30.5%) 261 (8.4%) | 128 (20.9%) 135 (22.0%) 90 (14.7%) 226 (36.9%) 34 (5.5%) | 705 (28.1%) 480 (19.2%) 369 (14.7%) 725 (28.9%) 227 (9.1%) | <0.001 |